華康生物醫學：環境、社會及管治報告2018.pdf

1、(incorporated in the Cayman Islands with limited liability)(於開曼群島註冊成立之有限公司)Stock Code 股份代號:8622ENVIRONMENTAL,SOCIAL AND GOVERNANCE REPORT Huakang Biomedical Holdings Company Limited華 康 生物醫學控股有限公司環 境、社 會 及管 治 報 告20181華康生物醫學控股有限公司 Huakang Biomedical Holdings Company LimitedENVIRONMENTAL,SOCIAL AND GOV

2、ERNANCE REPORT環境、社會及管治報告Huakang Biomedical Holdings Company Limited(hereinafter referred to as the“Company”,and“we”)has been engaged in the manufacturing of in-vitro diagnostic(“IVD”)reagents in China for over 15 years.During our business growth,we strive to be a responsible corporation and place st

3、rong emphasis on fulfilling our corporate social responsibility(“CSR”).To show our commitment,we are pleased to present this first environmental,social and governance(“ESG”)report detailing our material social and environmental performance of the Company as well as its subsidiaries(collectively,the“

4、Group”)for the reporting period from 1 January 2018 to 31 December 2018(“FY2018”).The Group maintains a close tie with its stakeholders,including shareholders,the government,employees,customers,suppliers,the community and the public,and strives to balance their opinions and interests through constru

5、ctive communications in order to determine the direction of its long-term development.Guided by their major concerns as identified during the stakeholder engagement process,we develop an approach to sustain our business development with the following three core areas.Business業務Conduct business with

6、integrity and deliver sustainable products and servicesWorkplaceCreate a workplace to improve employee satisfaction and retentionEnvironmentImprove the environment by reducing resources consumption and emissions以誠信經營業務，提供可持續的產品和服務工作間創建工作場所以提高僱員滿意度和保留率環境減少資源消耗及排放以改善環境華康生物醫學控股有限公司（以下簡稱為本公司 及 我們）於中國從事生